2-(methylamino)methylbenzimidazole dihydrochloride | 92809-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(methylamino)methylbenzimidazole dihydrochloride
• 英文别名: 1-(1H-benzimidazol-2-yl)-N-methylmethanamine dihydrochloride；dihydrochloride 2-(N-methylaminomethyl)benzimidazole；(1H-benzimidazol-2-ylmethyl)-methyl-amine; dihydrochloride；(1H-Benzimidazol-2-ylmethyl)-methyl-amin; Dihydrochlorid；2-(methylaminomethyl)benzimidazole dihydrochloride；1-(1H-benzimidazol-2-yl)-N-methylmethanamine;hydrochloride
• CAS: 92809-96-6
• 化学式: C₉H₁₁N₃*2ClH
• 分子量: 234.128
• InChiKey: ISTQRUATSNLAPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  40.7
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 储存条件：
  储存条件：密封、干燥、避光，存放在2-8°C环境中。

反应信息

• 作为反应物：
  描述：

  2-(methylamino)methylbenzimidazole dihydrochloride 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 (1H-苯并咪唑-2-甲基)甲胺
  参考文献：
  名称：

  BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

  摘要：

  公开号：

  EP1135374B9
• 作为产物：
  描述：

  2-氯甲基苯并咪唑 在 甲胺 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 以13%的产率得到2-(methylamino)methylbenzimidazole dihydrochloride
  参考文献：
  名称：

  Method for stimulating bone formation

  摘要：

  通过给予能够引发骨细胞释放骨钙蛋白的整合素结合化合物来刺激骨形成的方法被揭示。

  公开号：

  US20020032187A1

文献信息

• Cooperative Mn(<scp>i</scp>)-complex catalyzed transfer hydrogenation of ketones and imines
  作者：Kasturi Ganguli、Sujan Shee、Dibyajyoti Panja、Sabuj Kundu

  DOI：10.1039/c8dt05001e

  日期：——

  complex presented higher reactivity in the transfer hydrogenation (TH) of ketones in 2-propanol. Experimentally, it was established that both the benzimidazole and amine N–H proton played a vital role in the enhancement of the catalytic activity. Utilizing this system a wide range of aldehydes and ketones were reduced efficiently. Notably, the TH of several imines, as well as chemoselective reduction of

  据报道，带有双功能配体的Mn（I）配合物的合成和反应性均包含胺N-H和苯并咪唑片段。在各种配体中，含Mn（I）的N -（（1 H-苯并咪唑-2-基）甲基）苯胺配体）配合物在2-丙醇中酮的转移加氢（TH）中表现出更高的反应性。实验确定，苯并咪唑和胺NH质子均在增强催化活性中起着至关重要的作用。使用该系统可以有效地减少各种醛类和酮类。值得注意的是，在该催化剂的存在下，实现了几种亚胺的TH以及不饱和酮的化学选择性还原。进行DFT计算以了解合理的反应机理，该机理揭示了转移氢化反应遵循协调的外球机理。
• Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist
  申请人：SmithKline Beecham Corporation

  公开号：US05977101A1

  公开（公告）日：1999-11-02

  Vitronectin receptor antagonists having the formula: ##STR1## which are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporsis.

  Vitronectin受体拮抗剂的化学式为：##STR1##，可用于治疗炎症、癌症和心血管疾病，如动脉粥样硬化和再狭窄，以及骨吸收是因素的疾病，如骨质疏松症。
• Integrin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US06008213A1

  公开（公告）日：1999-12-28

  Compounds of formula (I) ##STR1## wherein A.sub.1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R.sup.3 or R.sup.4 ; X.sup.1 --X.sup.2 is CHR.sup.1 --CH, CR.sup.1 .dbd.CH, NR.sup.1 --CH, S(O).sub.u --CH or O--CH; X.sup.3 is CR.sup.5 R.sup.5 ', NR.sup.5, S(O).sub.u or O; R.sup.2 is --OR', --NR'R", --NR'SO.sub.2 R'", --NR'OR', --OCR'.sub.2 C(O)OR', --OCR'.sub.2 OC(O)--R', --OCR'.sub.2 C(O)NR'.sub.2, CF.sub.3 or --COCR'.sub.2 R.sup.2 '; R.sup.3, R.sup.4 and R.sup.7 are independently H, halo, --OR.sup.12, --SR.sup.12, --CN, --NR'R.sup.12, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r --, --CO.sub.2 R', --CONR'.sub.2, R.sup.14 --C.sub.0-6 alky-, R.sup.14 --C.sub.1-6 oxoalkyl-, R.sup.14 --C.sub.2-6 alkenyl-, R.sup.14 --C.sub.2-6 alkynyl-, R.sup.14 --C.sub.0-6 alkyloxy-, R.sup.14 --C.sub.0-6 alkylamino- or R.sup.14 --C.sub.0-6 alkyl--S(O).sub.r --; R.sup.6 is W--(CR'.sub.2).sub.q --Z--(CR'R.sup.10)--U--(CR'.sub.2).sub.s --V-- or W'--(CR'.sub.2).sub.q --U--(CR'.sub.2).sub.s -- U and V are absent or CO, CR'.sub.2, C(.dbd.CR.sup.15.sub.2), S(O).sub.n, O, NR.sup.15, CR.sup.15 'OR.sup.15, CR'(OR")CR'.sub.2, CR'.sub.2 CR'(OR") C(O)CR'.sub.2, CR.sup.15.sub.2 C(O), CONR.sup.15, NR.sup.15 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR.sup.15, NR.sup.15 C(S), SO.sub.2 NR.sup.15, NR.sup.15 SO.sub.2, N.dbd.N, NR.sup.15 NR.sup.15, NR.sup.15 CR.sup.15.sub.2, NR.sup.15 CR.sup.15.sub.2, CR.sup.15.sub.2 O, OCR.sup.15.sub.2, C$(m)ZC, CR.sup.15 .dbd.CR.sup.15, Het, or Ar, provided that U and V are not simultaneously absent, and W and W' are a nitrogen-containing substituent, and integrin receptor antagonists.

  式(I)的化合物##STR1##其中A.sub.1为C或N；E为一个五元或六元杂芳环或六元芳香环，可选择地被R.sup.3或R.sup.4取代；X.sup.1--X.sup.2为CHR.sup.1--CH，CR.sup.1.dbd.CH，NR.sup.1--CH，S(O).sub.u--CH或O--CH；X.sup.3为CR.sup.5R.sup.5'，NR.sup.5，S(O).sub.u或O；R.sup.2为--OR'，--NR'R"，--NR'SO.sub.2R'"，--NR'OR'，--OCR'.sub.2C(O)OR'，--OCR'.sub.2OC(O)--R'，--OCR'.sub.2C(O)NR'.sub.2，CF.sub.3或--COCR'.sub.2R.sup.2'；R.sup.3，R.sup.4和R.sup.7独立地为H，卤素，--OR.sup.12，--SR.sup.12，--CN，--NR'R.sup.12，--NO.sub.2，--CF.sub.3，CF.sub.3S(O).sub.r--，--CO.sub.2R'，--CONR'.sub.2，R.sup.14--C.sub.0-6烷基-，R.sup.14--C.sub.1-6氧代烷基-，R.sup.14--C.sub.2-6烯基-，R.sup.14--C.sub.2-6炔基-，R.sup.14--C.sub.0-6烷氧基-，R.sup.14--C.sub.0-6烷基氨基-或R.sup.14--C.sub.0-6烷基--S(O).sub.r--；R.sup.6为W--(CR'.sub.2).sub.q--Z--(CR'R.sup.10)--U--(CR'.sub.2).sub.s--V--或W'--(CR'.sub.2).sub.q--U--(CR'.sub.2).sub.s--U和V不存在或为CO，CR'.sub.2，C(.dbd.CR.sup.15.sub.2)，S(O).sub.n，O，NR.sup.15，CR.sup.15'OR.sup.15，CR'(OR")CR'.sub.2，CR'.sub.2CR'(OR")C(O)CR'.sub.2，CR.sup.15.sub.2C(O)，CONR.sup.15，NR.sup.15CO，OC(O)，C(O)O，C(S)O，OC(S)，C(S)NR.sup.15，NR.sup.15C(S)，SO.sub.2NR.sup.15，NR.sup.15SO.sub.2，N.dbd.N，NR.sup.15NR.sup.15，NR.sup.15CR.sup.15.sub.2，NR.sup.15CR.sup.15.sub.2，CR.sup.15.sub.2O，OCR.sup.15.sub.2，C$(m)ZC，CR.sup.15.dbd.CR.sup.15，Het或Ar，前提是U和V不同时不存在，且W和W'为含氮取代基，并且整合素受体拮抗剂。
• HETEROCYCLIC ACETAMIDE COMPOUND
  申请人：ASTELLAS PHARMA INC.

  公开号：US20140315963A1

  公开（公告）日：2014-10-23

  [Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

  [问题] 提供了一种作为多巴胺D1受体正变构调节剂（D1 PAM）有用的化合物。 [解决方案] 本发明的发明人已经研究了一种具有多巴胺D1受体正变构调节活性的化合物，该化合物作为用于预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药物组合物的有效成分是有用的，他们因此发现了一种杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，从而完成了本发明。本发明的杂环乙酰胺化合物具有多巴胺D1受体正变构调节活性，并且可以用作预防或治疗认知障碍、精神分裂症阴性症状、帕金森病、阿尔茨海默病、亨廷顿病、药物成瘾等的药剂。
• Structural and Electrochemical Studies of Some Cobalt(III) Complexes of 2-Aminomethylbenzimidazole and 2-(N-Methylaminomethyl)benzimidazole
  作者：Terence J. Cardwell、Alison J. Edwards、Richard M. Hartshorn、Rodney J. Holmes、W. David McFadyen

  DOI：10.1071/c96214

  日期：——

  A number of mixed-ligand cobalt(III) complexes containing either the ligand 2-aminomethylbenzimidazole (ambi) or its N-methyl derivative, namely 2-(N-methylaminomethyl)benzimidazole (mambi), have been prepared in relatively low yield; in particular, the complexes [Co(ambi)(acac)2] Cl, [Co(ambi)(Clacac)2] Cl, K[Co(ambi)(ox)2],[Co(ambi)2(acac)] (ClO4)2, [Co(mambi)(acac)2] Cl and [Co(mambi)(Clacac)2 ]Cl (acac = acetylacetonate, Clacac = 3-chloroacetylacetonate, ox = oxalate). The reduction potentials of these complexes have been measured in order to assess whether molecules of this type could be potential redox-activated hypoxic cell selective anticancer agents. The complex [Co(ambi)(acac)2] Cl.4·1H2O was characterized by single-crystal X-ray crystallography: a 19·425(1), b 17·734(1), c 15·979(1) Å, β 117·52(1)˚, monoclinic, space group C 2/c (No. 15)

  一些混合配体钴（III）配合物含有配体 2-aminomethylbenzimidazole (ambi) 或其 N-甲基 衍生物，即 2-（N-甲基氨基甲基）苯并咪唑（mambi）的混合配体钴（III）配合物。 或其 N-甲基衍生物，即 2-(N-甲基氨基甲基)苯并咪唑（曼比）。 [Co(ambi)(acac)2]Cl、 [Co(ambi)(Clacac)2]Cl、 K[Co(ambi)(ox)2]、[Co(ambi)2(acac) (ClO4)2、 [Co(mambi)(acac)2]Cl 和 [Co(mambi)(Clacac)2]Cl（acac = 乙酰丙酮酸，Clacac = 3-氯乙酰丙酮酸，ox = 草酸盐）。测量这些络合物的还原电位是为了 以评估这类分子是否可能成为潜在的 氧化还原激活的缺氧细胞选择性抗癌剂。复合物 [Co(ambi)(acac)2]。 Cl.4-1H2O。 X 射线晶体学表征：a 19-425(1)、 b 17-734(1), c 15-979(1)埃，β 117-52(1)˚，单斜，空间群 C 2/c（No. 空间群 C 2/c （No. 15)